Glutaral and Deciquam Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dual-active aqueous concentrate supplied for downstream formulation into the stated veterinary dosage forms. The designation should be read as a route-specific application range rather than a single universal formulation. Where the manufacturer assigns a model code, that code must be traceable on the certificate of analysis to the batch-specific glutaral-to-deciquam ratio, container closure system, and intended use. Glutaral, CAS 111-30-8, is a saturated five-carbon dialdehyde; deciquam is a didecyl dimethyl quaternary ammonium chloride. Release specifications normally comprise appearance as a clear to pale-yellow liquid, active assay by validated reversed-phase HPLC within ±5% of label claim, pH in the range 3.0–5.0, density 1.00–1.10 g/mL at 20 °C, and total viable aerobic count below 10² CFU/mL by Ph. Eur. 5.1.4. Because the fixed combination has no harmonised public monograph, the supplier must validate the deciquam assay as an ion-pair HPLC method against a certified reference material. The base concentrate is not intrinsically sterile; the word “injections” in the product title does not imply a ready-to-inject product, and endotoxin or sterility testing must be added when the downstream route requires it.

Does the Glutaral–Deciquam Ratio Influence Compatibility with Solid Dosage Form Excipients?

In tablet and granule production, the two actives follow different adsorption mechanisms. Glutaral is miscible in the aqueous granulating phase and reacts with primary amino groups on gelatin, hydrolysed collagen, or sodium caseinate binders; deciquam adsorbs electrostatically to anionic surfaces such as croscarmellose sodium, sodium starch glycolate, and microcrystalline cellulose. Formulation trials should begin with a zeta potential screen under ISO 13099-1:2012; a granulating suspension with a particle zeta potential more negative than −25 mV at pH 6.0 creates a high risk for deciquam retention on the disintegrant rather than release into the dissolution medium. When a 1:1 actives ratio is specified, published data for this fixed combination is limited, but single-active quaternary ammonium data show that deciquam recovery in the final blend can fall below 90% if anionic excipients are not pre-coated or pre-neutralised. The preferred granulation route is twin-screw wet granulation with a 25 L/D barrel, 0.5–1.5 mm die discharge, screw speed 200–400 rpm, and a barrel jacket set at 20–25 °C. This equipment maintains the temperature rise at the screw tip below 5 °C and limits the exposure time of glutaral to alkaline binder solutions.

Effervescent tablets and soluble granules impose a water-activity boundary. A wet granulation with water activity above 0.60 at 25 °C can initiate glutaral oligomerisation within 8 h; therefore the fluid-bed dryer should be operated with inlet air 40–50 °C, product temperature not exceeding 30 °C, and final moisture below 0.5% w/w by Karl Fischer titration per Ph. Eur. 2.5.12. A bin blender running at 10 rpm for 15 min is usually sufficient when deciquam is introduced as a pre-adsorbed silica carrier at 2–5% w/w of the blend. Direct spraying of liquid deciquam into a V-blender without dilution produces localised agglomerates and assay variation above 5% RSD across 10 sampling ports; that failure mode has been observed on production-scale 1000 L tumble blenders. Powders and premixes intended for drinking water or feed dilution should be manufactured in a ribbon blender with a 0.5% w/w mineral oil dust suppressant. Mineral oil above 1.0% w/w in the same blend reduces tablet hardness below 50 N when compressed on a rotary tablet press at 150 MPa maximum compaction pressure.

Aqueous pH Drift During High-Shear Granulation Limits Batch Duration

High-shear mixer granulation is possible only when alkaline components are separated from glutaral until the final wet massing step. Glutaral is most stable at pH 3.0–5.0; above pH 8 the molecule undergoes aldol condensation and forms oligomers that lose aldehyde titre. Deciquam remains cation-active over a wide pH range, but anionic surfactant traces in recycled water above 5 mg/L sodium lauryl sulfate can form insoluble ion pairs. In a high-shear granulator with a 600 L bowl and a main impeller speed of 120–180 rpm, the addition of sodium bicarbonate and citric acid used for effervescent tablets raises the local pH from 4.2 to 8.5 in less than 60 s before the granulating liquid is fully absorbed. This creates a processing window of ≤5 °C and ≤10 min for wet massing; beyond this window the glutaral assay loss can exceed 5% and the deciquam recovery in the dried granule can drift below 95%. A chopper speed of 1500 rpm reduces this pH excursion but does not eliminate it. The safer route is to granulate the acid component separately, dry to ≤0.3% moisture, and then lubricate and compress with an external lubrication system rather than batch blending.

Material Specifications, Pharmacopoeial Alignment, and Residue Limitations

Glutaral is controlled by Ph. Eur. 0408 and the corresponding USP concentrate monograph. Deciquam is controlled by an in-house ion-pair HPLC method with retention time verified against a reference standard of didecyl dimethyl ammonium chloride. For veterinary premix and solution dosage forms, the applicant should submit a validated stability-indicating assay covering glutaral, deciquam, and the main condensation products. The stability data must bracket the proposed container closure system. High-density polyethylene or polypropylene containers with torque-sealed caps are suitable; unlined carbon steel is not recommended because the acidic carrier can release iron. Natural rubber closures are incompatible because glutaral cross-links the stopper surface and may extract latex proteins. Residual glutaral on dairy equipment should be measured by HPLC after derivatisation with 2,4-dinitrophenylhydrazine; the numerical limit is set by the competent authority, and published data for a universal residue limit applicable to all species is limited.

Injectable dosage routes require a documented residue and toxicological rationale. Glutaral is not generally recognised as a direct injectable preservative in veterinary parenteral formulations; its main injectable-manufacturing role is as a cross-linker for gelatin-based microsphere carriers or as a vaccine toxoid inactivant after which residual free glutaral is removed by diafiltration or glycine quenching. Deciquam is not appropriate for systemic parenteral administration because of dose-dependent haemolysis observed in erythrocyte fragility assays at concentrations above 0.1% w/v; published data for the exact deciquam salt in target species is limited. Capsule production uses the solution primarily as a surface decontaminant for hard gelatin capsule shells, not as a capsule filler. The shell immersion bath is maintained at 0.2% v/v total actives and 25 °C, with a 5 min contact time and a subsequent water rinse. Bactericidal activity in that bath is verified by EN 13697:2015 surface testing against Staphylococcus aureus and Pseudomonas aeruginosa at 20 °C under clean conditions. The use of the same solution for sterilising filling needles does not replace steam sterilisation or depyrogenation; glutaral is not a depyrogenation agent.

When Glutaral–Deciquam Replaces Chlorhexidine in Teat Disinfection, Material Compatibility Changes

In predip and postdip solutions, the glutaral–deciquam system differs from chlorhexidine digluconate in residue, speed, and spectrum. Chlorhexidine leaves a persistent cationic film that is often measured by skin swabbing; deciquam forms a weaker film that is removed by milk fat unless a film-forming polymer such as hydroxypropyl methylcellulose is added at 0.1–0.3% w/w. Glutaral provides an aldehyde-based sporicidal and mycobactericidal mode of action that chlorhexidine does not display at use dilutions below 0.5% w/w. For efficacy claims in the veterinary field, the formulation must pass EN 1656:2009 suspension testing at 30 °C and 30 s contact in 0.3 g/L bovine albumin dirty conditions using hard water with 300 mg/L CaCO₃. A candidate dilution of 0.2% w/w glutaral and 0.1% w/w deciquam is expected to achieve ≥5 log reduction of Staphylococcus aureus ATCC 6538 and Escherichia coli ATCC 10536 under those conditions; if the marker organism is Mycobacterium avium subsp. paratuberculosis, the contact time must be extended and the dilution adjusted because published data for this specific combination is limited. In footbath applications the same active pair is used at higher total concentration, typically 1–2% w/w, with footbath renewal after 200–300 cow passes or when faecal organic loading exceeds 5% w/v.

Compared with benzalkonium chloride-based premixes, glutaral–deciquam has broader activity against bacterial spores but generates an odour threshold below 0.05 ppm in air; extraction fans with 10–12 air changes per hour are required in indoor handling areas. Compared with peracetic acid disinfectants, the product does not introduce hydrogen peroxide residuals but requires longer contact for Clostridium difficile spores. Equipment cleaned with the solution should not be rinsed with anionic detergents unless the anionic is completely removed, because quaternary ammonium inactivation occurs at sodium lauryl sulfate concentrations above 5 mg/L in the final rinse. High-density polypropylene footbaths and dosing pump lines are compatible; natural rubber and aluminium may degrade after repeated exposure.

The principal difference between the combined glutaral–deciquam API and single-active glutaral is the reduction in surface tension and the addition of a cationic detergency mechanism. The surface tension of a 0.2% w/v total active dilution measured by the Du Noüy ring method at 25 °C per ASTM D1331-20 typically falls from 72 mN/m for water to 28–32 mN/m; this improves contact on hydrophobic animal-housing surfaces but increases foam generation in clean-in-place circuits with air injection. Single-active glutaral does not provide the same wetting of fatty surfaces, but it produces fewer incompatible ion pairs with anionic excipients. Deciquam-only disinfectants are less sporicidal and mycobactericidal at farm-use dilutions; their advantage is lower odour and better skin tolerance. The combined product should not be mixed with amines, ammonia, sodium hypochlorite, or strong alkali, because glutaral polymerises and chlorinated by-products may form. Storage should be at 10–25 °C in closed containers; freezing below −5 °C can produce phase separation of the quaternary ammonium component, and thawing does not fully restore the original micellar distribution.